Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin as salvage therapy for platinum-resistant germ-cell tumors
2012-004508-36Phase 2Terminated
- Sponsor
- Michelangelo Foundation
- Start
- Mar 2013
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in Germ Cell Testicular Cancer, sponsored by Michelangelo Foundation. Primary endpoint: Overall response rate. Started Mar 2013; status: terminated.
02
Drugs
brentuximab vedotin
03
Conditions
Germ Cell Testicular Cancer
Beyond the preview
Go deeper on 2012-004508-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004508-36.